SCHEMBL4698775

SCHEMBL4698775

Cc1ccc(-c2nnn(-c3cccc(C#N)c3)n2)nc1

nearest known ligand 0.69

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 6/20 0.69
CHRNB2 P17787 1/20 0.58
CHRNA5 P30532 1/20 0.58
CHRNA4 P43681 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4701727 0.86 GRM5 (0.66) GRM5CHRNB2CHRNA5CHRNA4
SCHEMBL4698828 0.86 GRM5 (0.69) GRM5CHRNB2CHRNA5CHRNA4
SCHEMBL4700009 0.84 GRM5 (0.74) GRM5CHRNB2CHRNA5CHRNA4
SCHEMBL660355 0.81 GRM5 (1.00) GRM5
SCHEMBL4699145 0.81 GRM5 (0.69) GRM5CHRNB2CHRNA5CHRNA4
SCHEMBL4703078 0.81 GRM5 (0.68) GRM5CHRNB2CHRNA5CHRNA4
SCHEMBL4699227 0.80 GRM5 (0.74) GRM5CHRNB2CHRNA5CHRNA4
SCHEMBL4699771 0.79 GRM5 (0.66) GRM5CHRNB2CHRNA5CHRNA4
SCHEMBL4704590 0.78 GRM5 (0.61) GRM5CHRNB2CHRNA5CHRNA4
SCHEMBL4701815 0.77 GRM5 (0.67) GRM5CHRNB2CHRNA5CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1434773-B1 HETEROARYL SUBSTITUTED TETRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2008-05-21 EP claimed
US-7253190-B2 Heteroaryl substituted tetrazole modulators of metabotrophic glutamate receptor-5 MERCK & CO., INC. (US) 2007-08-07 US claimed
EP-1434773-A4 HETEROARYL SUBSTITUTED TETRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2005-01-12 EP claimed
US-20040186295-A1 Heteroaryl substituted tetrazole modulators of metabotrophic glutamate receptor-5 MERCK SHARP & DOHME LLC 2004-09-23 US claimed
EP-1434773-A2 HETEROARYL SUBSTITUTED TETRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Merck & Co., Inc. (US) 2004-07-07 EP claimed
WO-2004030637-A2 TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE MERCK & CO., INC. (US) 2004-04-15 WO claimed
WO-2003029210-A2 HETEROARYL SUBSTITUTED TETRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO. INC. (US) 2003-04-10 WO claimed
US-7253190-B2 Heteroaryl substituted tetrazole modulators of metabotrophic glutamate receptor-5 MERCK & CO., INC. (US) 2007-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186295-A1 Heteroaryl substituted tetrazole modulators of metabotrophic glutamate receptor-5 GRM5, GRM1, GRIK5 GRM5 1/4885CHRNB2 535/4885CHRNA5 86/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.